Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
THEOLIXIR vs AEROLATE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Theophylline is a xanthine derivative that acts as a competitive nonselective phosphodiesterase inhibitor, increasing intracellular cyclic AMP levels, and as an antagonist at adenosine receptors (A1 and A2 subtypes), leading to bronchodilation, anti-inflammatory effects, and stimulation of respiratory drive.
Theophylline competitively inhibits phosphodiesterase, increasing c AMP levels, and acts as an adenosine receptor antagonist, leading to bronchodilation and reduced airway inflammation.
Treatment of symptoms and reversible airway obstruction associated with chronic asthma,Chronic obstructive pulmonary disease (COPD)
FDA-approved: Treatment of asthma and chronic obstructive pulmonary disease (COPD),Off-label: Apnea of prematurity, bradycardia in preterm infants
Oral: 200-400 mg every 6 hours (maximum 1600 mg/day) as sustained-release tablets or liquid. Inhalation: Not applicable.
For asthma and COPD: 1-2 inhalations (90 mcg each) via metered-dose inhaler, 2 puffs twice daily, maximum 4 puffs twice daily. For acute exacerbations: 4-8 puffs every 20 minutes for up to 4 hours, then every 1-4 hours as needed.
Terminal elimination half-life is 3–5 hours in adults (nonsmokers), but prolonged to 6–8 hours in neonates, elderly, and patients with hepatic cirrhosis or heart failure. Smoking (tobacco or marijuana) reduces half-life to 1–2 hours due to enzyme induction.
Terminal elimination half-life 12 hours; clinical context: q12h dosing achieves steady-state in 2-3 days
Hepatic metabolism via CYP1A2, CYP2E1, and CYP3A4. Approximately 10% excreted unchanged in urine.
Primarily hepatic via CYP1A2 and CYP3A4; also metabolized by xanthine oxidase and N-acetyltransferase. Metabolites excreted renally.
Renal excretion of unchanged drug accounts for approximately 10% of elimination; the remainder is hepatically metabolized, with 80% excreted in urine as metabolites (1-methyluric acid and 3-methylxanthine) and less than 10% in feces.
Renal (80% as unchanged drug), biliary/fecal (15% as metabolites), 5% other
Approximately 40% bound to albumin (primarily), with some binding to alpha-1-acid glycoprotein; binding is reduced in neonates and patients with hypoalbuminemia.
65% bound to albumin
0.3–0.7 L/kg; approximates total body water. Higher Vd in neonates (0.8 L/kg) due to increased extracellular fluid. Clinically, loading dose calculation uses Vd = 0.5 L/kg.
2.5 L/kg (extensive tissue distribution, suggests high lung penetration)
Oral immediate-release: 96–100% (virtually complete); sustained-release formulations: 80–100% (dependent on formulation and food effects).
Oral: 40% (first-pass metabolism); Inhaled: 20% (lung deposition)
No adjustment required for GFR >30 m L/min. For GFR 10-30 m L/min: reduce dose by 50% and increase interval to every 12 hours. For GFR <10 m L/min: give 200 mg every 12-24 hours.
No dose adjustment required for renal impairment. Drug is primarily hepatically metabolized and renally excreted as inactive metabolites; however, significant accumulation is not expected in renal dysfunction.
Child-Pugh A: no change. Child-Pugh B: reduce dose by 50% (maximum 800 mg/day). Child-Pugh C: reduce dose by 75% (maximum 400 mg/day) or increase interval to every 12-24 hours.
Child-Pugh Class A: No dose adjustment. Class B: Reduce dose to 50% of normal, monitor for adverse effects. Class C: Use with caution; reduce dose to 25-50% and monitor closely. Specific data for AEROLATE limited; adjust based on clinical response and tolerance.
Oral: Initial 5 mg/kg/dose every 6 hours; titrate to target serum concentration of 5-15 mcg/m L. Maximum: 20 mg/kg/day or 800 mg/day, whichever lower.
Children 4-11 years: 1-2 inhalations (90 mcg each) twice daily; maximum 2 inhalations twice daily. Children 12 years and older: Same as adult dosing. Administer via inhaler with spacer for optimal delivery. Weight-based dosing not typically used; fixed doses per age group.
Start at lowest adult dose (200 mg every 6 hours) and monitor serum levels; decreased clearance may necessitate lower maintenance doses. Maximum daily dose 800 mg.
No specific dose adjustment required. Use lowest effective dose due to potential for increased systemic exposure from reduced clearance and higher risk of adverse effects (e.g., osteoporosis, hyperglycemia). Monitor for cardiac effects and adrenal suppression.
No FDA black box warning.
No FDA black box warning.
Narrow therapeutic index; serum levels should be monitored to avoid toxicity,Risk of seizures, arrhythmias, and death at high concentrations,Caution in patients with hepatic impairment, congestive heart failure, pulmonary edema, or fever,Potential for drug interactions with CYP1A2 inhibitors/inducers
Monitor serum theophylline levels due to narrow therapeutic index (10-20 mcg/m L).,Risk of toxicity at high levels: seizures, arrhythmias, death.,Use with caution in patients with hepatic impairment, heart failure, fever, or elderly.,Cigarette smoking and certain drugs (e.g., rifampin, phenytoin) induce metabolism; others (e.g., cimetidine, macrolides) inhibit metabolism.
Hypersensitivity to theophylline or any component of the formulation,Pre-existing cardiac arrhythmias (especially tachyarrhythmias)
Hypersensitivity to theophylline or any component.,Active peptic ulcer disease.,Uncontrolled seizure disorders.
High-fat meals may alter theophylline absorption, leading to variable serum concentrations. Avoid excessive intake of caffeine-containing foods and beverages (e.g., coffee, tea, cola, chocolate) as they can potentiate stimulant effects and increase risk of toxicity. Charcoal-broiled foods may increase theophylline clearance, reducing efficacy.
Avoid excessive caffeine intake (coffee, tea, cola, chocolate) as it may potentiate CNS stimulation and toxicity. Food does not significantly affect absorption, but high-fat meals may delay absorption. Consistent dietary habits are recommended.
Theophylline (active ingredient in THEOLIXIR) is not a major human teratogen. First trimester: Limited data show no consistent association with major malformations. Second/Third trimesters: Fetal tachycardia and jitteriness may occur at maternal therapeutic levels; toxicity can cause neonatal irritability, vomiting, and apnea. Risk of preterm labor or low birth weight not established.
AEROLATE (theophylline) is classified as FDA Pregnancy Category C. First trimester: No well-controlled studies; potential risk cannot be excluded. Second and third trimesters: Theophylline crosses the placenta and can cause fetal tachycardia, jitteriness, and irritability; apneic episodes and respiratory failure reported in neonates exposed near term. Risk of preterm labor and low birth weight associated with maternal asthma exacerbation.
Theophylline is excreted into breast milk with M/P ratio approximately 0.6-0.7. Average infant dose ~1.5% of maternal weight-adjusted dose. Considered compatible with breastfeeding; observe infant for irritability or sleep disturbance, especially with maternal doses >800 mg/day or high serum levels.
Theophylline is excreted into breast milk with an M/P ratio of approximately 0.67. Peak milk levels occur 1-2 hours after maternal dosing. Estimated infant dose is about 1-10% of maternal weight-adjusted dose. Caution: irritability and jitteriness reported in breastfed infants. Avoid breastfeeding if maternal serum theophylline levels exceed 20 mcg/m L.
Pregnancy increases clearance of theophylline by 30-70% due to enhanced hepatic metabolism and increased renal elimination. Dose adjustments may be required to maintain therapeutic levels; monitor serum concentrations and adjust accordingly, especially in the third trimester. Postpartum clearance returns to prepregnancy levels, requiring downward dose adjustment.
Pregnancy may increase theophylline clearance (especially in second and third trimesters) due to increased renal perfusion and hepatic metabolism. Dose adjustments often required to maintain therapeutic levels. Initiate at standard dose and titrate based on serum levels and clinical response. Postpartum clearance decreases rapidly; doses should be reduced to pre-pregnancy levels within 2-4 weeks after delivery.
Theophylline (THEOLIXIR) has a narrow therapeutic index; serum levels should be maintained between 5-15 mcg/m L. Levels >20 mcg/m L increase toxicity risk. Administer with food if GI upset occurs, but avoid high-fat meals as they may increase absorption variability. Use with caution in patients with cardiac dysfunction, seizures, or peptic ulcer disease. Monitor for drug interactions with macrolides, fluoroquinolones, and cimetidine which decrease clearance.
AEROLATE (theophylline) has a narrow therapeutic index; monitor serum levels (target 5-15 mcg/m L). Avoid in patients with active peptic ulcer disease or seizure disorders unless essential. Caution with hepatic impairment, heart failure, and in elderly due to reduced clearance. Drug interactions: cimetidine, fluoroquinolones, macrolides, and CYP1A2 inhibitors increase levels; smoking and rifampin decrease levels.
Take this medication exactly as prescribed; do not skip doses or double up.,Do not crush or chew extended-release tablets; swallow whole.,Get your blood levels checked regularly as directed by your doctor.,Avoid consuming large amounts of caffeine (coffee, tea, soda, chocolate) as it may increase side effects like jitteriness or rapid heartbeat.,Inform your doctor if you experience nausea, vomiting, restlessness, insomnia, or rapid heartbeat.,Do not stop taking this medicine suddenly without consulting your doctor.
Take exactly as prescribed; do not change dose or frequency without consulting your doctor.,If you miss a dose, take it as soon as you remember unless it is almost time for the next dose; do not double the dose.,Avoid consuming large amounts of caffeine (coffee, tea, cola, chocolate) as it may increase side effects.,Contact your doctor if you experience nausea, vomiting, insomnia, rapid heartbeat, or seizures.,Do not smoke or stop smoking without informing your doctor, as smoking affects the drug's metabolism.,Keep a list of all medications you take, including over-the-counter drugs and herbal supplements.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about THEOLIXIR vs AEROLATE, answered by our medical review team.
THEOLIXIR is a Bronchodilator that works by Theophylline is a xanthine derivative that acts as a competitive nonselective phosphodiesterase inhibitor, increasing intracellular cyclic AMP levels, and as an antagonist at adenosine receptors (A1 and A2 subtypes), leading to bronchodilation, anti-inflammatory effects, and stimulation of respiratory drive.. AEROLATE is a Bronchodilator that works by Theophylline competitively inhibits phosphodiesterase, increasing c AMP levels, and acts as an adenosine receptor antagonist, leading to bronchodilation and reduced airway inflammation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between THEOLIXIR and AEROLATE depend on the specific clinical indication. These are both Bronchodilator agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of THEOLIXIR is: Oral: 200-400 mg every 6 hours (maximum 1600 mg/day) as sustained-release tablets or liquid. Inhalation: Not applicable.. The standard adult dose of AEROLATE is: For asthma and COPD: 1-2 inhalations (90 mcg each) via metered-dose inhaler, 2 puffs twice daily, maximum 4 puffs twice daily. For acute exacerbations: 4-8 puffs every 20 minutes for up to 4 hours, then every 1-4 hours as needed.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between THEOLIXIR and AEROLATE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. THEOLIXIR is classified as Category C. Theophylline (active ingredient in THEOLIXIR) is not a major human teratogen. First trimester: Limited data show no consistent association with major malformations. Second/Third tr. AEROLATE is classified as Category C. AEROLATE (theophylline) is classified as FDA Pregnancy Category C. First trimester: No well-controlled studies; potential risk cannot be excluded. Second and third trimesters: Theo. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.